Abstract：
:There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival advantage of approximately 5% at 5 years and is now generally accepted for patients with stage II-IIIA disease, adjuvant therapy for patients with stage I disease is more controversial. In this review we describe approaches to improve treatment outcomes and ongoing research into new therapies in the adjuvant setting. In the future it is likely that patient selection on the basis of gene signatures and biomarkers will be of increasing importance in determining optimal treatment for individual patients. New targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, angiogenesis inhibitors, and anticancer immunotherapies are showing activity in the advanced disease setting and are being studied for incorporation into multimodal adjuvant treatment approaches. It is hoped that such advances and a changing treatment paradigm will ultimately result in greater survival for patients with early NSCLC.
journal_name
Clin Lung Cancerjournal_title
Clinical lung cancerauthors
Carbone DP,Felip Edoi
10.1016/j.cllc.2011.06.002subject
Has Abstractpub_date
2011-09-01 00:00:00pages
261-71issue
5eissn
1525-7304issn
1938-0690pii
S1525-7304(11)00137-9journal_volume
12pub_type
杂志文章,评审abstract：BACKGROUND:The aim of this trial was to determine feasibility of incorporating bevacizumab (B) into concurrent chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Patients with unresectable stage III NSCLC, performance status of 0 to 1, and adequate organ function were...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2014.12.014
更新日期：2015-09-01 00:00:00
abstract：INTRODUCTION:The programmed death 1 antibodies (PD-1 Ab) nivolumab and pembrolizumab improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC). We evaluated the correlation between immune-related adverse events (irAE) and treatment interruption due to irAE on clinical efficacy of PD-1 Ab in advanced ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cllc.2018.09.005
更新日期：2019-01-01 00:00:00
abstract：:The identification of tumor biomarkers provides information on the prognosis and guides the implementation of appropriate treatment in patients with many different cancer types. In non-small cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification have already been used in the clinic. Howev...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2014.06.005
更新日期：2014-11-01 00:00:00
abstract：BACKGROUND:In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this hypothesis, we analyzed TP53 mutations and downregulation of p14(arf), a negative regulator of p53 activated by on...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.08.003
更新日期：2014-03-01 00:00:00
abstract：:The ability to reliably distinguish synchronous primary non-small-cell lung cancer (NSCLC) from intrapulmonary metastatic spread affects staging and treatment decisions in resected NSCLC. Adjuvant therapy for early-stage NSCLC is complicated and recommendations are primarily based on older data from trials that used n...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2015.03.004
更新日期：2015-09-01 00:00:00
abstract：BACKGROUND:The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS:To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.005
更新日期：2017-11-01 00:00:00
abstract：BACKGROUND:A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2014.06.001
更新日期：2015-01-01 00:00:00
abstract：INTRODUCTION:Economic analyses of upcoming treatments for lung cancer benefit from real-world health utility scores (HUSs) in an era of targeted therapy. METHODS:A longitudinal cohort study at Princess Margaret Cancer Centre evaluated 1571 EQ5D-3L-derived HUSs in 475 outpatients with metastatic lung cancer across vari...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.12.015
更新日期：2017-07-01 00:00:00
abstract：BACKGROUND:Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS:Seventy-two patients with poor PS and advanced NSCLC were enrolled onto this study of gefitinib 250 ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CLC.2005.n.028
更新日期：2005-09-01 00:00:00
abstract：:This phase I/II study was conducted to evaluate the safety and efficacy of tirapazamine in combination with cisplatin and vinorelbine for patients with advanced-stage IIIB/IV chemonaive non-small-cell lung cancer. Seventy patients with a Karnofsky performance status of > or = 60% were included. In the phase I part of ...
journal_title：Clinical lung cancer
pub_type： 临床试验,杂志文章,多中心研究
doi：10.3816/clc.2005.n.008
更新日期：2005-03-01 00:00:00
abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2016.05.006
更新日期：2016-11-01 00:00:00
abstract：BACKGROUND:Obtaining a tissue diagnosis has traditionally been standard practice before initiating therapy for early-stage non-small-cell lung cancer (NSCLC). In several recent studies from Europe and Asia, a substantial proportion of patients have received stereotactic body radiation therapy (SBRT) based only on the i...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2014.04.001
更新日期：2014-07-01 00:00:00
abstract：:The success of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in numerous tumor types including non-small-cell lung cancer (NSCLC) has spurred the development of additional novel antiangiogenic agents with distinct mechanisms of action. These include the small-molecule receptor tyrosine kinase...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2006.n.010
更新日期：2006-03-01 00:00:00
abstract：BACKGROUND:Evidence favoring a multidisciplinary team (MDT) approach in the treatment of lung cancer is scarce, especially in the United States. The purpose of the present investigation was to evaluate survival outcomes of lung cancer patients treated with an MDT compared with a traditional care model. PATIENTS AND ME...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2018.01.006
更新日期：2018-07-01 00:00:00
abstract：INTRODUCTION/BACKGROUND:The aim of this study was to identify imaging-based predictors of progression in patients treated with SABR for stage I NSCLC. PATIENTS AND METHODS:Between March 2003 and December 2012, 117 patients with stage I NSCLC meeting our study criteria were treated with SABR at Stanford University. Med...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.12.011
更新日期：2014-07-01 00:00:00
abstract：:Antisense oligonucleotides (ASONs) are one of the new classes of molecularly targeted agents that have transitioned from the laboratory into clinical trials. Rational drug design has resulted in agents directed against a number of important cellular targets, including the mRNA of bcl-2, protein kinase (PK) C-alpha, PK...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.2003.s.007
更新日期：2003-01-01 00:00:00
abstract：:Lung cancer remains the number one cause of cancer-based mortality in men and women. The importance of proper lung cancer care outside of major academic centers cannot be overemphasized because the vast majority of lung cancer care occurs in community hospital settings. We have had the opportunity to develop a highly ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2009.n.032
更新日期：2009-07-01 00:00:00
abstract：BACKGROUND:Standard treatment for stage III non-small-cell lung cancer (NSCLC) is concurrent chemotherapy and radiation (chemo-RT). However, N3 stage IIIB disease portends a worse prognosis and the tolerability of chemo-RT in patients ≥70 years old is a concern. In this analysis, we evaluate the survival of patients wi...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.04.003
更新日期：2019-07-01 00:00:00
abstract：BACKGROUND:In advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), liquid biopsy (LB) is routinely used to evaluate the presence of EGFR T790M as an acquired...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2020.02.021
更新日期：2020-09-01 00:00:00
abstract：:Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2016.05.016
更新日期：2016-11-01 00:00:00
abstract：UNLABELLED:Non–small-cell lung carcinoma (NSCLC) (n = 65) were analyzed for promoter methylation of RASSF1A, CDH13, MGMT, ESR1, and DAPK genes in matching lung tumors, normal lung tissue, and blood samples. Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC. Hypermethylation ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.11.003
更新日期：2012-07-01 00:00:00
abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.12.007
更新日期：2014-05-01 00:00:00
abstract：PURPOSE:Lung cancer is an epidemic disease in developing countries. Incorporation of new active drugs in the neoadjuvant treatment of operable patients might lead to improved outcomes. Postchemotherapy mediastinal-based treatment decisions allow for in vivo testing of activity and could help to determine the ideal loca...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2007.n.003
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Central nervous system (CNS) progression is a common manifestation of acquired resistance to crizotinib in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). However, an optimal tailored treatment approach has not been established in patients with CNS failure during crizotinib tr...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.06.013
更新日期：2019-11-01 00:00:00
abstract：BACKGROUND:Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS:We reviewed 187 patients with NSCLC pN1-N2 w...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.04.012
更新日期：2013-11-01 00:00:00
abstract：:The therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC) are palliative. Therefore, the quality of life in oncology is considered as an endpoint in clinical trials, and several scales have been accepted for its measurement in parallel with other clinical determinations. However, its use in...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2009.n.010
更新日期：2009-03-01 00:00:00
abstract：BACKGROUND:First-line treatment of non-small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but also the efficacy of ICIs through blockade of vascular endothelial growth ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2020.03.010
更新日期：2020-09-01 00:00:00
abstract：OBJECTIVE:The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS:Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-squ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.009
更新日期：2017-11-01 00:00:00
abstract：UNLABELLED:Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. M...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.05.001
更新日期：2015-11-01 00:00:00
abstract：:An early phase II study of topotecan produced favorable results in a small number of untreated and previously treated patients with small-cell lung cancer (SCLC). This multicenter study was conducted in patients with relapsed SCLC at 19 medical institutions in Japan. Topotecan 1.0 mg/m2/day was administered for 5 cons...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.2003.n.002
更新日期：2003-01-01 00:00:00
